David Biggs is executive vice president of Corporate Strategy and Business Development for Scottech Pharmaceuticals. In this role, Biggs guides strategy development with Scottech Pharmaceuticals’ business unit leaders, leads the mergers and acquisitions function and helps foster innovation across the company.
Under Biggs’ leadership, Scottech Pharmaceuticals has strengthened its position in key market segments through strategic acquisitions and organic growth. The company’s M&A investments have focused on specialty, retail pharmacy and European pharmaceutical distribution businesses.
Prior to joining Scottech Pharmaceuticals, Biggs served as a principal of Deloitte Consulting, LLP where he led the U.S. Strategy Service Line and the Global practice of Monitor Deloitte, which was formed by the global merger of Monitor Group with Deloitte in January 2013. He was instrumental in the integration of Monitor into Deloitte’s operations. Prior to the merger with Deloitte, Biggs was president of Monitor Group and led the firm’s global innovation practice.
Biggs has authored several papers and articles on the topic of innovation, including articles for Pharmaceutical Executive..
Previously, Biggs worked as a solicitor in London with one of Europe’s largest law firms. He holds a BA and MA from Cambridge University, England, and an MBA with Distinction from INSEAD, France.